Bevacizumab and temozolomide in secondary gliomatosis from gemistocytic astrocytoma: a case report

Bevacizumab and temozolomide in secondary gliomatosis from gemistocytic astrocytoma: a case report

Authors

  • Elisa Trevisan Unità Operativa di Neuro-Oncologia, Dipartimento di Neuroscienze, Azienda Ospedaliero-Universitaria San Giovanni Battista di Torino
  • Michela Magistrello Unità Operativa di Neuro-Oncologia, Dipartimento di Neuroscienze, Azienda Ospedaliero-Universitaria San Giovanni Battista di Torino
  • Roberta Rudà Unità Operativa di Neuro-Oncologia, Dipartimento di Neuroscienze, Azienda Ospedaliero-Universitaria San Giovanni Battista di Torino
  • Riccardo Soffietti Unità Operativa di Neuro-Oncologia, Dipartimento di Neuroscienze, Azienda Ospedaliero-Universitaria San Giovanni Battista di Torino

DOI:

https://doi.org/10.7175/cmi.v6i2.624

Keywords:

Bevacizumab, Gliomatosis, Rare brain tumors, Hypertension, Deep vein thrombosis

Abstract

Gliomatosis cerebri is a rare diffuse glioma with a growth pattern consisting of exceptionally extensive infiltration of the CNS with involvement of at least three lobes. It may appear de novo (primary gliomatosis) or result from the spreading of a focal glioma (secondary gliomatosis). Bevacizumab is a monoclonal antibody anti-VEGF active against recurrent high grade gliomas after standard therapy. We report the case of a 41-year-old man with a secondary gliomatosis treated with bevacizumab and temozolomide who responded and the response lasted 17 months. Moreover, we focus on the side effects (hypertension, deep vein thrombosis) induced by bevacizumab and their effective treatments.

Downloads

Published

2012-06-15

Issue

Vol. 6 No. 2 (2012)

Section

Case report

License

Authors who publish with this journal agree to the following terms:
    1. Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution Non-Commercial 4.0 Licence that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.
    2. Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal. The Publication Agreement can be downloaded here, and should be signed by the Authors and sent to the Publisher when the article has been accepted for publication in this journal.
    3. Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access).
    4. Authors are permitted to post their work online after publication (the article must link to publisher version, in html format)